We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Labcorp's Q4 Earnings Preview: What's in Store for the Stock?
Read MoreHide Full Article
Key Takeaways
Labcorp will report Q4 results on Feb. 17, with revenues expected to climb 6.6% to $3.55 billion.
LH's Diagnostics segment is projected to post 8.4% revenue growth from acquisitions and tests.
Labcorp's Biopharma Laboratory Services unit is expected to grow 3.1% despite restructuring hard comps.
Labcorp Holdings Inc. (LH - Free Report) , or Labcorp, is slated to report its fourth-quarter 2025 results on Feb. 17, before the market opens.
The renowned laboratory service provider reported adjusted earnings of $4.18 in the last reported quarter, topping the Zacks Consensus Estimate by 1.21%. Labcorp surpassed estimates in each of the trailing four quarters, the average surprise being 2.68%.
Q4 Estimates for LH
The Zacks Consensus Estimate for Labcorp’s fourth-quarter 2025 revenues is pegged at $3.55 billion. This suggests a 6.6% rise from the year-ago reported figure.
The Zacks Consensus Estimate for its fourth-quarter 2025 EPS indicates an improvement of 15% to $3.95.
Estimate Revision Trend Ahead of Labcorp’s Q4 Earnings
Estimates for Labcorp’s fourth-quarter earnings have remained constant at $3.95 in the past 30 days.
Here’s a brief overview of the company’s progress ahead of this announcement.
LH: Factors at Play
Diagnostics Laboratories (Dx)
The segment is likely to have continued its strong momentum, supported by organic growth and contributions from acquisitions. Over the past several years, Labcorp’s strategic relationships with health systems and regional/local laboratories have expanded its patient and provider network and strengthened its presence in key markets. Recent additions include the acquisition of Incyte Diagnostics’ clinical pathology (CP) business, select assets of the outreach business from Community Health Systems across 13 states, and select oncology and clinical testing assets from BioReference Health. We expect these additions to have favorably supported the company’s revenues in the fourth quarter of 2025.
Demand for the core test menu is likely to have remained strong across high-growth specialty areas, including oncology, women's health, neurology and autoimmune diseases. The company has introduced several testing capabilities, including the availability of OmniSeq INSIGHT Genomic Profiling with homologous recombination deficiency (HRD) reporting, and wider access to Invitae genetic tests through Epic Aura. PGDx elio tissue’s complete status as the only tissue-based tumor profiling test with CE-IVDR marking may have enhanced global tissue profiling capabilities in support of clinical trials. We assume these developments to have positively aided the company’s top line in the fourth quarter of 2025.
Labcorp is also likely to have witnessed continued strong adoption for its consumer-initiated tests through the Labcorp OnDemand channel. The company had partnered with Praia Health, a consumer experience platform for health systems, to help close care gaps and deliver better experiences for patients.
The Zacks Consensus Estimate indicates a 7% year-over-year increase in the Dx segment’s revenues.
Biopharma Laboratory Services (“BLS”)
The segment is likely to have continued to benefit from the strength of the Central Laboratories, its largest component. Early Development revenues were impacted by delayed study starts in the previous quarter, prompting Labcorp to divest or restructure through site consolidation, impacting roughly $50 million in annual revenues in non-core areas. During the October earnings call, management indicated that the fourth quarter of 2025 presents the most challenging year-over-year comparison for this business.
The Zacks Consensus Estimate suggests that revenues in the BLS segment are likely to grow 3.1% year over year.
Across the organization, Labcorp’s increased use of science and technology may have strongly favored growth and operational efficiency. The company introduced Test Finder, a generative AI tool developed with Amazon Web Services, to improve test selection for providers and health systems. Other recent innovative initiatives include the Labcorp Diagnostic Assistant and eClaim Assist tool.
Within core laboratory operations, Labcorp is also investing in digital and AI capabilities to improve in areas such as pathology, cytology and microbiology. The Launchpad initiative is likely to achieve its targeted $100-$125 million in annual savings, supporting the company’s margins in the fourth quarter.
Earnings Whispers for Labcorp
Per our proven model, stocks with a Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 (Hold), along with a positive Earnings ESP, have a higher chance of beating estimates, which is not the case here, as you can see below:
Earnings ESP: Labcorp has an Earnings ESP of 0.00%. You can uncover the best stocks to buy or sell before they’re reported with our Earnings ESP Filter.
Zacks Rank: The company currently carries a Zacks Rank #4 (Sell).
Here are some medical stocks worth considering, as these have the right combination of elements to post an earnings beat this time:
Veracyte (VCYT - Free Report) has an Earnings ESP of +7.98% and a Zacks Rank #1. The company is set to release fourth-quarter 2025 results on Feb. 25.
VCYT’s earnings surpassed estimates in each of the trailing four quarters, the average surprise being 45.12%. The Zacks Consensus Estimate for the company’s fourth-quarter EPS suggests an increase of 13.9% from the year-ago quarter figure.
Globus Medical (GMED - Free Report) has an Earnings ESP of +3.92% and a Zacks Rank #2. The company is expected to release fourth-quarter 2025 results soon.
GMED’s earnings beat estimates in three of the trailing four quarters and missed on one occasion, the average surprise being 16.24%. The Zacks Consensus Estimate for the company’s fourth-quarter EPS implies a surge of 26.2% from the year-ago reported figure.
Merit Medical Systems (MMSI - Free Report) has an Earnings ESP of +2.09% and a Zacks Rank #2. The company is slated to release fourth-quarter 2025 results on Feb. 24.
MMSI’s earnings topped estimates in each of the trailing four quarters, the average surprise being 14.1%. The Zacks Consensus Estimate for the company’s fourth-quarter EPS calls for an increase of 3.2% from the year-ago quarter’s figure.
Zacks' 7 Best Strong Buy Stocks (New Research Report)
Valued at $99, click below to receive our just-released report
predicting the 7 stocks that will soar highest in the coming month.
View the Zacks #1 Rank List
Image: Bigstock
Labcorp's Q4 Earnings Preview: What's in Store for the Stock?
Key Takeaways
Labcorp Holdings Inc. (LH - Free Report) , or Labcorp, is slated to report its fourth-quarter 2025 results on Feb. 17, before the market opens.
The renowned laboratory service provider reported adjusted earnings of $4.18 in the last reported quarter, topping the Zacks Consensus Estimate by 1.21%. Labcorp surpassed estimates in each of the trailing four quarters, the average surprise being 2.68%.
Q4 Estimates for LH
The Zacks Consensus Estimate for Labcorp’s fourth-quarter 2025 revenues is pegged at $3.55 billion. This suggests a 6.6% rise from the year-ago reported figure.
The Zacks Consensus Estimate for its fourth-quarter 2025 EPS indicates an improvement of 15% to $3.95.
Estimate Revision Trend Ahead of Labcorp’s Q4 Earnings
Estimates for Labcorp’s fourth-quarter earnings have remained constant at $3.95 in the past 30 days.
Here’s a brief overview of the company’s progress ahead of this announcement.
LH: Factors at Play
Diagnostics Laboratories (Dx)
The segment is likely to have continued its strong momentum, supported by organic growth and contributions from acquisitions. Over the past several years, Labcorp’s strategic relationships with health systems and regional/local laboratories have expanded its patient and provider network and strengthened its presence in key markets. Recent additions include the acquisition of Incyte Diagnostics’ clinical pathology (CP) business, select assets of the outreach business from Community Health Systems across 13 states, and select oncology and clinical testing assets from BioReference Health. We expect these additions to have favorably supported the company’s revenues in the fourth quarter of 2025.
Demand for the core test menu is likely to have remained strong across high-growth specialty areas, including oncology, women's health, neurology and autoimmune diseases. The company has introduced several testing capabilities, including the availability of OmniSeq INSIGHT Genomic Profiling with homologous recombination deficiency (HRD) reporting, and wider access to Invitae genetic tests through Epic Aura. PGDx elio tissue’s complete status as the only tissue-based tumor profiling test with CE-IVDR marking may have enhanced global tissue profiling capabilities in support of clinical trials. We assume these developments to have positively aided the company’s top line in the fourth quarter of 2025.
Labcorp Holdings Inc. Price and EPS Surprise
Labcorp Holdings Inc. price-eps-surprise | Labcorp Holdings Inc. Quote
Labcorp is also likely to have witnessed continued strong adoption for its consumer-initiated tests through the Labcorp OnDemand channel. The company had partnered with Praia Health, a consumer experience platform for health systems, to help close care gaps and deliver better experiences for patients.
The Zacks Consensus Estimate indicates a 7% year-over-year increase in the Dx segment’s revenues.
Biopharma Laboratory Services (“BLS”)
The segment is likely to have continued to benefit from the strength of the Central Laboratories, its largest component. Early Development revenues were impacted by delayed study starts in the previous quarter, prompting Labcorp to divest or restructure through site consolidation, impacting roughly $50 million in annual revenues in non-core areas. During the October earnings call, management indicated that the fourth quarter of 2025 presents the most challenging year-over-year comparison for this business.
The Zacks Consensus Estimate suggests that revenues in the BLS segment are likely to grow 3.1% year over year.
Across the organization, Labcorp’s increased use of science and technology may have strongly favored growth and operational efficiency. The company introduced Test Finder, a generative AI tool developed with Amazon Web Services, to improve test selection for providers and health systems. Other recent innovative initiatives include the Labcorp Diagnostic Assistant and eClaim Assist tool.
Within core laboratory operations, Labcorp is also investing in digital and AI capabilities to improve in areas such as pathology, cytology and microbiology. The Launchpad initiative is likely to achieve its targeted $100-$125 million in annual savings, supporting the company’s margins in the fourth quarter.
Earnings Whispers for Labcorp
Per our proven model, stocks with a Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 (Hold), along with a positive Earnings ESP, have a higher chance of beating estimates, which is not the case here, as you can see below:
Earnings ESP: Labcorp has an Earnings ESP of 0.00%. You can uncover the best stocks to buy or sell before they’re reported with our Earnings ESP Filter.
Zacks Rank: The company currently carries a Zacks Rank #4 (Sell).
You can see the complete list of today’s Zacks #1 Rank stocks here.
Key MedTech Picks
Here are some medical stocks worth considering, as these have the right combination of elements to post an earnings beat this time:
Veracyte (VCYT - Free Report) has an Earnings ESP of +7.98% and a Zacks Rank #1. The company is set to release fourth-quarter 2025 results on Feb. 25.
VCYT’s earnings surpassed estimates in each of the trailing four quarters, the average surprise being 45.12%. The Zacks Consensus Estimate for the company’s fourth-quarter EPS suggests an increase of 13.9% from the year-ago quarter figure.
Globus Medical (GMED - Free Report) has an Earnings ESP of +3.92% and a Zacks Rank #2. The company is expected to release fourth-quarter 2025 results soon.
GMED’s earnings beat estimates in three of the trailing four quarters and missed on one occasion, the average surprise being 16.24%. The Zacks Consensus Estimate for the company’s fourth-quarter EPS implies a surge of 26.2% from the year-ago reported figure.
Merit Medical Systems (MMSI - Free Report) has an Earnings ESP of +2.09% and a Zacks Rank #2. The company is slated to release fourth-quarter 2025 results on Feb. 24.
MMSI’s earnings topped estimates in each of the trailing four quarters, the average surprise being 14.1%. The Zacks Consensus Estimate for the company’s fourth-quarter EPS calls for an increase of 3.2% from the year-ago quarter’s figure.